Here is My Question:
In your opinion does Lemtrada have more risks than Ocrevus? We asked the new doctor about Lemtrada and she said she wouldn’t refuse to prescribe it but thinks it’s more risky than Ocrevus. They have no patients taking Lemtrada and stated there really isn’t a “market share” for Lemtrada. My husband didn’t like the use of sales terms! Thoughts?
In my opinion, Lemtrada is riskier than the b-cell biological (rituxan and ocrevus). Secondary autoimmunity with Lemtrada is of concern and requires close monitoring throughout treatment but also years after stopping therapy. I suspect the market share comment reflects the reality that Lemtrada isn’t considered as a go to therapy unless patients fail other effective therapies due to its significant risks.
A. Scott Nielsen MD MMSc
Neurologist and MS Specialist at Kaiser Permanente
PLEASE NOTE: This information/opinions on this site should be used as an information source only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.